Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck (NYSE:MRK) announced Wednesday that a Phase 3 trial designed to test its anti-PD-1 therapy Keytruda (pembrolizumab) as ...

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Keytruda cuts risk of death by 20% in certain patients with gastric or gastroesophageal junction as a first-line combination ...

Merck is studying Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, in a raft of trials across a wide variety of cancers and treatment settings. The company is ...

Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less ...

Merck (MRK) announced the Japanese Ministry of Health, Labor and Welfare has approved new indications for KEYTRUDA or pembrolizumab, ...

Keytruda shows promise as a first line option in cervical cancer cutting patients' mortality risk by a third in a Phase 3 ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...